United Therapeutics Corporation ($UTHR) Stock Forecast: Down 5.3% Today

What is United Therapeutics Corporation?

United Therapeutics (UTHR) is a pharmaceutical company specializing in treatments for pulmonary arterial hypertension (PAH) and other medical conditions. The stock demonstrated a significant bearish movement today.

Why is United Therapeutics Corporation going down?

UTHR stock is down 5.3% on Mar 3, 2026 15:13

• Price targets for UTHR were raised by Jefferies and other firms after the positive Phase 3 trial results of its drug ralinepag for PAH treatment, showing a 55% reduction in clinical worsening risk.
• Despite the encouraging trial outcomes and analyst positivity, UTHR's stock saw a bearish movement, possibly attributed to profit-taking following recent gains.
• The company's recent product launches and advancements in xenotransplantation may have played a role in its robust stock performance over the previous year, although today's market movement could be influenced by broader market conditions or technical factors.
• Investors are advised to monitor UTHR's upcoming FDA submission for ralinepag and its revenue targets for potential future catalysts.

UTHR Price Chart

UTHR Technical Analysis

UTHR News

Jefferies raises United Therapeutics stock price target on trial data

Jefferies has raised its price target for United Therapeutics Corp. (NASDAQ:UTHR) stock to $668 from $640, maintaining a Buy rating, following positive Phase 3 trial results for its drug ralinepag in treating pulmonary arterial hypertension. The trial demonstrated a 55% risk reduction in clinical worsening, performing well across patient subgroups and achieving statistical significance. Other firms like H.C. Wainwright, Leerink Partners, and TD Cowen have also increased their price targets and reiterated positive ratings, citing the promising trial data and growth outlook for the company's portfolio.

https://m.investing.com/news/analyst-ratings/jefferies-raises-united-therapeutics-stock-price-target-on-trial-data-93CH-4536184?ampMode=1

United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening

United Therapeutics (NASDAQ: UTHR) saw its stock rise after announcing positive phase 3 trial results for its drug ralinepag, which demonstrated a 55% reduction in clinical worsening events for patients with pulmonary arterial hypertension (PAH). The study also showed a 47% increase in clinical improvement odds and a good safety profile, with the company planning an FDA submission by mid-2026. Despite a broader market decline, UTHR's gains reflect company-specific success, and analysts have recently raised price targets for the stock.

https://www.benzinga.com/trading-ideas/movers/26/03/50969566/united-therapeutics-trial-shows-55-drop-in-lung-disease-worsening

United Therapeutics: Ralinepag cuts risk of clinical worsening by 55% in pivotal PAH trial

United Therapeutics announced that its drug ralinepag reduced the risk of clinical worsening by 55% in the phase 3 ADVANCE OUTCOMES study for pulmonary arterial hypertension (PAH). The study met its primary endpoint, showing significant benefits in secondary measures like 6-minute walk distance and NT-proBNP levels, with a safety profile consistent with known prostacyclin-related events. The company plans to submit a New Drug Application (NDA) to the FDA by the second half of 2026.

https://www.tradingview.com/news/tradingview:b0ede28199db8:0-united-therapeutics-ralinepag-cuts-risk-of-clinical-worsening-by-55-in-pivotal-pah-trial/

United Therapeutics Tresmi Launch And Xenotransplant Progress Shape Valuation Story

United Therapeutics (UTHR) has launched Tresmi, a new soft mist inhaler, and reported record annual revenue, while also making progress in its xenotransplantation program. These developments have contributed to the company's strong stock performance, with shares up 55.6% over the past year. Analysts see potential upside for UTHR, with Simply Wall St estimating the stock to be significantly undervalued.

https://www.sahmcapital.com/news/content/united-therapeutics-tresmi-launch-and-xenotransplant-progress-shape-valuation-story-2026-02-27

United Therapeutics Corporation (NASDAQ:UTHR) Given Average Recommendation of "Moderate Buy" by Brokerages

United Therapeutics Corporation (NASDAQ:UTHR) has received a "Moderate Buy" consensus recommendation from twelve analysts, with an average 12-month price target of $533.55. The company recently beat EPS estimates for Q4 but missed on revenue, and management aims for a $4B revenue run-rate by 2027. Despite significant insider selling, institutional investors hold a substantial portion of the company's stock.

https://www.marketbeat.com/instant-alerts/united-therapeutics-corporation-nasdaquthr-given-average-recommendation-of-moderate-buy-by-brokerages-2026-02-28/

Trending Today

United Therapeutics Corporation Price History

06.00.2026 - UTHR Stock was up 5.0%

• Today's positive movement in UTHR stock is linked to the company's Chairperson and CEO speaking at the J.P. Morgan Healthcare Conference, underlining their dedication to innovation and addressing medical needs.
• Institutional investors, including Merit Financial Group LLC and Allspring Global Investments Holdings LLC, have increased their stake in the company, showing confidence in its future growth despite recent insider transactions.
• An analysis of the rotational strategy timing suggests short-term sentiment may be weak. However, the focus remains on UTHR's long-term potential and fundamentals, indicating investors are looking beyond immediate fluctuations.

07.04.2025 - UTHR Stock was up 5.2%

• A dispute filed by United Therapeutics against Liquidia was dismissed by the District Court.
• UTHR's Q1 earnings and revenues exceeded estimates, driven by increased Tyvaso sales.
• The favorable legal outcome and strong financial results are believed to have influenced the bullish movement in UTHR's stock price today.

01.07.2025 - UTHR Stock was up 5.1%

• The reasons for the bullish movement in UTHR stock are:
• Strong Tyvaso sales contributing to a 12% increase in revenues year-over-year.
• Despite missing earnings estimates for the second quarter, the market reacted positively to the company's revenue growth.
• The announcement of a share repurchase program of up to $1 billion by the company's board may have instilled confidence in investors concerning future prospects.
• Investors seem to be concentrating more on the revenue growth and potential of the company's product portfolio rather than short-term earnings misses.

03.02.2026 - UTHR Stock was down 5.3%

• Price targets for UTHR were raised by Jefferies and other firms after the positive Phase 3 trial results of its drug ralinepag for PAH treatment, showing a 55% reduction in clinical worsening risk.
• Despite the encouraging trial outcomes and analyst positivity, UTHR's stock saw a bearish movement, possibly attributed to profit-taking following recent gains.
• The company's recent product launches and advancements in xenotransplantation may have played a role in its robust stock performance over the previous year, although today's market movement could be influenced by broader market conditions or technical factors.
• Investors are advised to monitor UTHR's upcoming FDA submission for ralinepag and its revenue targets for potential future catalysts.

26.01.2026 - UTHR Stock was down 5.5%

• UTHR shares dropped by nearly 5% as the company missed Q4 revenue estimates while surpassing earnings expectations. This discrepancy could raise concerns among investors regarding the company's future growth trajectory.
• The company's operating margin declined year-on-year, indicating potential issues in cost management or operational efficiency that may have contributed to the market's negative response.
• Insider trading activities by the President and COO, involving the sale of shares at a specific price, could have impacted market sentiment, leading to a bearish trend as investors analyzed this move.
• Even though UTHR's Tyvaso product line and strategic efforts performed well, the market's attention on the revenue miss and insider trading overshadowed the positive financial results, causing a decline in the stock price.

25.01.2026 - UTHR Stock was up 11.2%

• The positive stock movement in UTHR is possibly linked to insider trading by President and COO Michael Benkowitz, who recently exercised stock options and sold shares at a noteworthy price, signaling confidence in the company's performance.
• Investors are looking forward to the upcoming Q4 earnings report, expecting a year-over-year revenue growth despite previous revenue estimate misses. This anticipation could potentially drive the stock price up.
• The FDA's recent approval of Tyvaso dry powder inhaler for treating PAH and PH-ILD, a product developed by United Therapeutics, may have influenced investor sentiment positively. This showcases the company's dedication to innovation and addressing unmet medical needs in the market.

02.08.2025 - UTHR Stock was up 0.8%

• Following the announcement of an expanded collaboration with MannKind Corporation for a second inhaled therapy, United Therapeutics (UTHR) witnessed a notable increase in its stock price. This development likely instilled confidence in investors regarding the company's growth potential and the possibility of new revenue streams.
• The positive market response could also be linked to the upcoming earnings report of United Therapeutics, adding to the optimistic outlook for the company's financial performance. As the stock continues to rise, investors appear hopeful about its future prospects.
• Today's bullish movement in UTHR's stock reflects the favorable progress in collaboration initiatives and the market's optimistic view of the company's future in the pharmaceutical sector.

30.06.2025 - UTHR Stock was down 5.4%

• UTHR reported Q2 earnings that missed analyst estimates on both the top and bottom lines, leading to a bearish movement in the stock.
• The company's announcement of a share repurchase program of up to $1 billion did not seem to offset the disappointment from the earnings miss.
• The stock crossing above the 50-day moving average could have initially signaled a positive trend, but the earnings results likely overshadowed this technical indicator, causing the bearish movement.
• Investors may be concerned about the company's future performance based on the Q2 results, leading to a sell-off in the stock.

29.09.2025 - UTHR Stock was up 8.3%

• UTHR experienced a strong bullish movement today by surpassing Q3 earnings estimates, exceeding expectations by 3.92%.
• The anticipation of earnings growth leading up to the upcoming report has likely bolstered the positive sentiment, showcasing faith in the company's future performance.
• Investors appear hopeful about UTHR's prospects, given its consistent delivery of favorable outcomes and ability to meet market expectations, resulting in an increase in the stock price.

10.05.2025 - UTHR Stock was down 10.7%

• UTHR's bearish movement could be attributed to profit-taking by investors after a period of growth or due to concerns about the company's future performance.
• The potential struggles of Corcept (CORT) after their last earnings report may have had a spillover effect on UTHR, causing investors to be cautious about the biotechnology sector as a whole.
• Investors might be reevaluating their positions in biotech stocks, leading to a broader sell-off in the sector and impacting UTHR negatively.
• It is essential for investors to closely monitor both company-specific news and industry trends to make informed decisions in the volatile biotechnology market.

30.06.2025 - UTHR Stock was down 4.2%

• UTHR stock witnessed a significant decline in value today.
• Falling short of Q2 earnings estimates by -5.74% potentially influenced the downward trajectory.
• Although surpassing the 50-day moving average, investors' response to the earnings disappointment likely drove the negative trend.
• Investor sentiment concerning UTHR may be influenced by apprehensions regarding future performance following the recent earnings outcome.

29.09.2025 - UTHR Stock was up 9.7%

• UTHR stock showed a strong bullish movement today, likely influenced by the company surpassing Q3 earnings expectations.
• Despite revenues falling below projections, the robust performance of Tyvaso and Orenitram contributed to the positive earnings surprise.
• Investor optimism regarding potential growth opportunities in the coming quarters may be fueled by the earnings beat.
• Market trends indicate that investors are more focused on the positive earnings surprise and growth potential, overshadowing the revenue shortfall and driving the bullish momentum in UTHR stock.